Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | PC_BETS substudy C: darolutamide in mCRPC pretreated with ARPIs

Michael Ong • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer Darolutamide
PC_BETS

Michael Ong, MD, BSc, FRCPC, The Ottawa Hospital Cancer Centre, Ottawa, Canada, discusses findings from substudy C of the Phase II PC_BETS trial (NCT04161180), which evaluated darolutamide in metastatic castration-resistant prostate cancer (mCRPC) following prior androgen-receptor pathway inhibitor treatment (ARPIs). Patients were stratified by circulating tumor DNA alterations in the androgen receptor. Clinical benefit was more frequently observed in those with AR amplification or specific mutations. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Ong

The significance of PSA levels in prostate cancer prognosis
1:09
The significance of PSA levels in prostate cancer prognosis
Michael Ong • 1 Jun 2025
Prognostic impact of PSA thresholds in mHSPC after ADT-ARPI
2:27
Prognostic impact of PSA thresholds in mHSPC after ADT-ARPI
Michael Ong • 1 Jun 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals